Presentation is loading. Please wait.

Presentation is loading. Please wait.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,

Similar presentations


Presentation on theme: "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,"— Presentation transcript:

1 Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley, Eric H. Bernicker, Carol Colasacco, Sanja Dacic, Fred R. Hirsch, Keith Kerr, David J. Kwiatkowski, Marc Ladanyi, Jan A. Nowak, Lynette Sholl, Robyn Temple-Smolkin, Benjamin Solomon, Lesley H. Souter, Erik Thunnissen, Ming S. Tsao, Christina B. Ventura, Murry W. Wynes, Yasushi Yatabe  The Journal of Molecular Diagnostics  Volume 20, Issue 2, Pages (March 2018) DOI: /j.jmoldx Copyright © 2018 College of American Pathologists, International Association for the Study of Lung Cancer, Association for Molecular Pathology, and American Society for Investigative Pathology Terms and Conditions

2 Figure 1 Forest plot of sensitivity and specificity for immunohistochemistry (IHC)-based determination of ROS1 rearrangement positivity compared with fluorescence in situ hybridization. Pooled estimate of sensitivity and specificity based on bivariate analysis of included studies. All included studies used an IHC staining intensity of at least 2+ with a D4D6 antibody to define ROS1 rearrangement positivity. FN, false-negative; FP, false-positive; TN, true-negative; TP, true-positive. The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx ) Copyright © 2018 College of American Pathologists, International Association for the Study of Lung Cancer, Association for Molecular Pathology, and American Society for Investigative Pathology Terms and Conditions

3 Figure 2 Forest plot of sensitivity and specificity for immunohistochemistry-based determination of ALK translocation positivity compared with fluorescence in situ hybridization. Pooled estimate of sensitivity and specificity based on bivariate analysis of included studies. Included studies assessed 5A4, D5F3, or either 5A4 or D5F3 antibodies with positivity cutoffs based on either presence of any staining or staining intensity. FN, false-negative; FP, false-positive; neg, negative; pos, positive; TN, true-negative; TP, true-positive. The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx ) Copyright © 2018 College of American Pathologists, International Association for the Study of Lung Cancer, Association for Molecular Pathology, and American Society for Investigative Pathology Terms and Conditions

4 Figure 3 Forest plot of sensitivity and specificity for various assays determining EGFR mutation positivity with cell-free DNA compared with tumor tissue. Pooled estimate of sensitivity and specificity based on bivariate analysis of included studies. Four included studies compared tumor tissue samples with plasma samples using the same detection system,234,235,242,243 and a fifth study232 obtained plasma samples from patients with known EGFR and KRAS tumor mutation status. ARMs, amplification refractory mutation system; ddPCR, droplet digital PCR; FN, false-negative; FP, false-positive; PCR, polymerase chain reaction; PNA/LNA, peptide nucleic acid–locked nucleic acid; TN, true-negative; TP, true-positive. The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx ) Copyright © 2018 College of American Pathologists, International Association for the Study of Lung Cancer, Association for Molecular Pathology, and American Society for Investigative Pathology Terms and Conditions


Download ppt "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors  Neal I. Lindeman,"

Similar presentations


Ads by Google